Zydus Cadila built on "strong pipeline" in recent Abbott deal
This article was originally published in Scrip
Zydus Cadila's chairman and managing director, Pankaj Patel, has dismissed suggestions that the company's recent deal with Abbott was indicative of an increasing trend where Indian companies would rather play the "safe" role of manufacturer, instead of developing their own markets and taking on the competition.
You may also be interested in...
The termination of the Aurobindo-Sandoz deal isn’t perhaps all bad news for the Indian firm and the flip side may be an improved balance sheet, according to some analysts. But the resolution of compliance issues at manufacturing facilities remains critical.
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.